New treatment approach for gastric cancer targeting tumor fibrin
Theranostic for gastric cancer
This study is looking at a new treatment for advanced gastric cancer that focuses on a substance called fibrin found in tumors, hoping to make the therapy more effective and improve outcomes for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Collagen Medical, LLC NIH-funded |
| Lab location | 1 site (Boston, UNITED STATES) |
| Project ID | NIH-11141271 on NIH RePORTER |
What this research studies
This research aims to improve the management of gastric cancer by developing a therapy that targets fibrin in the tumor microenvironment. Gastric cancer is a serious condition with a poor prognosis, and current treatments have limited effectiveness. The approach involves using high energy beta particle radiotherapy specifically directed at fibrin, which is abundant in tumors but not in healthy tissues. By utilizing advanced imaging techniques, the therapy seeks to enhance treatment outcomes for patients with advanced gastric cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced gastric cancer who have not responded well to standard therapies.
Not a fit: Patients with early-stage gastric cancer or those whose tumors do not exhibit significant fibrin deposition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for gastric cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While targeting fibrin in tumors is a novel approach, similar strategies using targeted therapies have shown promise in other cancer types, suggesting potential for success in this area.
Where this research is happening
Boston, UNITED STATES
- Collagen Medical, LLC — Boston, United States (Active)
Researchers
- Principal investigator: Humblet, Valerie — Collagen Medical, LLC
- Study coordinator: Humblet, Valerie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.